Transforming the
Immunotherapy Landscape


Safe and Effective Immunotherapies

Amberstone Biosciences’ transformative immunotherapeutics eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. Traditional therapies can be extremely effective at destroying tumors. However, the high dosage required for efficacy often has devastating effects. Our technology (T-MATE™) allows us to target only the tumor without damaging healthy tissues. 

T-MATE to Traditional Comparison Wide_Square copy (3)

Safer Therapeutic Strategy

Our transformative therapeutic strategy allows for revisiting targets previously deemed impossible due to high toxicity.


Our pipeline strategy is adaptable to various tumor types or auto-immune diseases.

Selectively Activated

Our therapeutics only activate under specified conditions and deactivate when conditions are no longer desirable.

Diverse Library of Therapeutic Agents

Our unique combinations of engagers and agonists create an expandable portfolio of therapeutic targets.


Isolation and Engineering of Rare Functional Clones

Pipeline therapeutic discoveries start with our AmberFlow™ platform technology. Driven by proprietary single-cell microfluidics, AmberFlow™ adds the element of a directly assayable and tunable microenvironment so valuable qualitative data can be obtained much further upstream in the discovery process. 


Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology
January 03, 2022 LAGUNA HILLS, Calif. BUSINESS WIRE
Read More
Amberstone Biosciences Announces Formation of Scientific Advisory Board
June 27, 2022 LAGUNA HILLS, Calif, PRNewswire
Read More
Previous slide
Next slide

Pioneer a new wave of therapeutic breakthroughs.